Study claims antidepressants benefit only small portion of patients

Share this article:

A new study of prescription antidepressants published this week suggests the drugs may be no more effective than placebo in treating the most common forms of depression.

“Although patients get better when they take antidepressants, they also get better when they take a placebo, and the difference in improvement is not very great,” said the study's lead researcher Irving Kirsch, a professor of psychology at the University of Hull in Great Britain, in a prepared statement. “This means that depressed people can improve without chemical treatments.”

Kirsch and colleagues collected data on 35 clinical trials of antidepressant selective serotonin reuptake inhibitors (SSRIs) submitted to the FDA. Drugs in the trials included fluoxetine (Prozac), venlafaxine (Effexor), nefazodone (Serzone) and paroxetine (Paxil). 

According to Kirsch's analysis of the data, patients taking the antidepressant drugs fared no better than patients taking placebo. The result appeared to be the same in patients who were mildly or moderately depressed. The antidepressants appeared to benefit a small group of patients with severe depression, the study found.

The findings were published online Feb. 25 in the journal PLoS Medicine. For more, information click here.

Global sales of antidepressants were approximately $21 billion in 2007.

Share this article:
close

Next Article in News

Email Newsletters

More in News

BI rethinks hepatitis business, posts 2013 results

BI rethinks hepatitis business, posts 2013 results

Boehringer Ingelheim says it is no longer pursuing an interferon-free combination of faldaprevir and deleobuvir.

Roche wraps quarter with two fewer pipeline medications

Roche wraps quarter with two fewer pipeline medications

Roche also announced first-quarter sales shrank 1%.

2013 favored specialists, specialty Rx

2013 favored specialists, specialty Rx

The latest IMS Institute for Healthcare Informatics assessment of 2013's prescription drug use shows that 2.3% of prescriptions account for 30% of a patient's out-of-pocket prescription costs.